Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round

NMD Pharma develops new treatments, improving the signaling of the nerves to the muscles, to patients suffering from orphan motor neuron diseases including Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). The company has identified a novel disease target and developed new small molecule drug-like compounds effectively increasing neuromuscular transmission. In models of neuromuscular disease, animals treated with these compounds were able to run five-fold longer than controls. With the investment, NMD Pharma will further optimize and characterize their lead compounds in preparation for selecting a preclinical candidate.

The research that led to the discovery was conducted in the muscle electrophysiology laboratory of the NMD founders, Associate Professor Thomas Holm Pedersen and Professor Ole Bækgaard Nielsen in close collaboration with senior researcher and co-founder Claus Elsborg Olesen at Aarhus University, Denmark.

“NMD Pharma is a clear-cut example of how basic research has the potential to create new and innovative treatments to patients with unmet needs” said Thomas Holm Pedersen, CEO of NMD Pharma

Patrick Vink, M.D. will join NMD Pharma as Chairman of the board of directors. Patrick Vink most recently served as chief operating officer of Cubist Pharmaceuticals, joining there from senior roles at Mylan Inc. Previously Patrick Vink held several leadership positions with Novartis Sandoz, Sanofi and Biogen, principally in global commercial roles. Further, Stephan Christgau, Novo Seeds, Christian Elling, Lundbeckfonden Emerge and founder Claus Elsborg Olesen will join the board.

“NMD Pharma is based on cutting edge electrophysiology science combined with deep knowledge in motor neuron diseases. We are excited to take part in the seed financing and help grow the company to address important unmet needs of patients with motor neuron disease” said Christian Elling, Lundbeckfonden Emerge.

“NMD Pharma is a spectacular example of a successful combination of excellent science and highly talented people which are key components in creating a successful biotech start-up. We are happy to have been able to assist in the creation of NMD Pharma, first by a pre-seed grant, and now in the first investment in the company” said Stephan Christgau, Novo Seeds.

“We are excited to take part in the financing of NMD Pharma. Our mission is to turn Danish innovation into new business’ creating new sustainable jobs and growth to our region. We look forward to working with the company in our shared goal of translating their discoveries into a new business” said Otto Bjerg Hausgaard, Capnova.

Lundbeckfonden Emerge is the early stage investment unit of Lundbeckfonden, one of the largest industrial foundations in Denmark with a market value of more than DKK 50 billion. In addition to the three subsidiaries, Lundbeck, ALK-Abelló and Falck, the Foundation manages a portfolio of more than 20 life science investments in Europe and the US and owns a portfolio of securities of approx. DKK 14 billion. For more information, visit www.lundbeckfonden.com

Novo Seeds is the early stage investment unit of Novo A/S. Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S. Novo A/S provides seed, venture and growth capital to development stage companies within life science and biotechnology, as well as manages a broad portfolio of financial assets. For more information, visit www.novo.dk

CAPNOVA is an investment and development company which by means of capital, business experience and a strong network turns innovative ideas into successful businesses. Since the introduction of the Danish government’s Innovation Incubator Scheme in 1998, CAPNOVA has established more than 250 new businesses and facilitated investments of DKK 2 billion. CAPNOVA invests in projects that initiate their main activity in Denmark. CAPNOVA has a portfolio of over 100 businesses.
For further information, please contact:

Thomas Holm Pedersen, CEO

thp@nmdpharma.com+45 2059 6838


DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge